These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31803482)

  • 1. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.
    Patel S; Abreu M; Tumyan A; Adams-Huet B; Li X; Lingvay I
    BMJ Open Diabetes Res Care; 2019; 7(1):e000761. PubMed ID: 31803482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
    Abreu M; Tumyan A; Elhassan A; Peicher K; Papacostea O; Dimachkie P; Siddiqui MS; Pop LM; Gunasekaran U; Meneghini LF; Adams-Huet B; Li X; Lingvay I
    Diabetes Obes Metab; 2019 Sep; 21(9):2133-2141. PubMed ID: 31144435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication regimen complexity and its impact on medication adherence and glycemic control among patients with type 2 diabetes mellitus in an Ethiopian general hospital.
    Ayele AA; Tegegn HG; Ayele TA; Ayalew MB
    BMJ Open Diabetes Res Care; 2019; 7(1):e000685. PubMed ID: 31321061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of patient education on KAP, medication adherence and therapeutic outcomes of metformin versus insulin therapy in patients with gestational diabetes: A Hospital based pilot study in South India.
    Krishnakumar S; Govindarajulu Y; Vishwanath U; Nagasubramanian VR; Palani T
    Diabetes Metab Syndr; 2020; 14(5):1379-1383. PubMed ID: 32755838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L; Vaag A; Tarnow L; Almdal TP; Lund SS; Wetterslev J; Gluud C; Boesgaard TW; Wiinberg N; Perrild H; Krarup T; Snorgaard O; Gade-Rasmussen B; Thorsteinsson B; Røder M; Mathiesen ER; Jensen T; Vestergaard H; Hedetoft C; Breum L; Duun E; Sneppen SB; Pedersen O; Hemmingsen B; Carstensen B; Madsbad S
    BMJ Open; 2016 Feb; 6(2):e008377. PubMed ID: 26916685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
    Gao L; Zhang P; Weng J; Lu J; Guo X; Jia W; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Li X; Zhu D; Wu Y; Garg SK; Ji L
    J Diabetes; 2020 Sep; 12(9):668-676. PubMed ID: 32329194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.
    Zhang P; Chen M; Zhang H; Luo Y; Zhu D; Li X; Ji J; Wang D; Duolikun N; Ji L
    BMC Endocr Disord; 2022 Jan; 22(1):26. PubMed ID: 35045841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
    Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
    Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
    Inoue Y; Nakamura A; Kondo Y; Hamano K; Satoh S; Terauchi Y
    J Clin Pharmacol; 2015 Jul; 55(7):831-8. PubMed ID: 25677642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
    DeVries JH; Bain SC; Rodbard HW; Seufert J; D'Alessio D; Thomsen AB; Zychma M; Rosenstock J;
    Diabetes Care; 2012 Jul; 35(7):1446-54. PubMed ID: 22584132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
    Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
    J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of structured education in patients with type 2 diabetes mellitus receiving insulin treatment.
    Guo XH; Ji LN; Lu JM; Liu J; Lou QQ; Liu J; Shen L; Zhang MX; Lv XF; Gu MJ
    J Diabetes; 2014 Jul; 6(4):290-7. PubMed ID: 24279284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.